Marinus H van Hulst (Marinus van Hulst)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 10

Top Topics

Atrial Fibrillation

Venous Thromboembolism

Direct Oral Anticoagulants

Top Venues

PharmacoEconomics

The European journal of health economics : HEPAC : health economics in prevention and care

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics 42 (6) (2024)
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics (2024)
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics 42 (6) (2024)
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics 42 (6) (2024)
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics 42 (6) (2024)
Jeroen H J Paulissen, Ahmed H Seddik, Kyle J Dunton, Christopher J Livings, Marinus H van Hulst, Maarten Jacobus Postma, Lisa Aniek de Jong, Roel D Freriks
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland. The European journal of health economics : HEPAC : health economics in prevention and care (2023)
Marinus H van Hulst, Robert G Tieleman, Lennaert A R Zwart, Marc Pomp, Maartje S Jacobs, Joan G Meeder, Clara E E van Ofwegen-Hanekamp, Monika Hollander, Paul Smits, Martin E W Hemels
Health economic evaluation of nation-wide screening programmes for atrial fibrillation in the Netherlands. European heart journal. Quality of care & clinical outcomes (2022)
Martijn R Brands, Jelmer Sytema, Marinus H van Hulst, Arvid W A Kamps
Unintentional ingestion of a high dose of acenocoumarol in a young child. BMJ case reports 14 (4) (2021)
Lucia van der Veen, Marijn Segers, Jos Jam van Raay, Carina LE Gerritsma-Bleeker, Reinoud W Brouwer, Nic Jgm Veeger, Marinus H van Hulst
Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study. BMJ open 11 (1) (2021)
Marinus H van Hulst, Jelena Stevanovic, Maartje S Jacobs, Robert G Tieleman, Bregt Kappelhoff, Maarten J Postma
The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. Journal of medical economics 21 (1) (2017)